The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.
about
A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centersRecognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic reviewNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewYellow fever vaccine induces integrated multilineage and polyfunctional immune responsesConformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complexLMO2 and BCL6 are associated with improved survival in primary central nervous system lymphomaGene selection and cancer type classification of diffuse large-B-cell lymphoma using a bivariate mixture model for two-species data.The Stanford Tissue Microarray DatabaseCharacterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domainOptimization based tumor classification from microarray gene expression data.Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profilingMicroRNAs of the immune system: roles in inflammation and cancer.Follicular lymphoma: still Six characters in search of an author?Immunoarchitectural patterns in nodal marginal zone B-cell lymphoma: a study of 51 cases.Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomasPoor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategiesExpression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alphaC-C chemokine receptor 1 expression in human hematolymphoid neoplasiaThe transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survivalLMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGALDiffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisComparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomasGenetic barcode sequencing for screening altered population dynamics of hematopoietic stem cells transduced with lentivirusmiR-155 regulates HGAL expression and increases lymphoma cell motility.The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity.Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice.LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.High expression of LMO2 predicts a favorable outcome in adult patients with BCR/ABL negative B-cell acute lymphoblastic leukemia.Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP ConThe efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrowLow stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary originMachine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
P2860
Q24318306-6891AD02-099D-4300-BBD5-68A924335954Q26996650-583530AB-5D6A-41D3-A853-0FB712D0C7D4Q27304386-88626AF6-E0C6-4240-BF0D-D39B98A3A360Q27487514-FC8D45F8-30DF-42D8-9F9A-E8CA0ED29A46Q27681258-F2DFF6AF-D2BD-4DD6-B1C5-AD9DB8C3DD9BQ30389426-AD17E6C4-B407-4795-B5C6-DBA0E75FC366Q30584472-F7C2F1EC-8927-4312-9F82-1E7F682C81CEQ33305327-D2BD1851-634E-4DE5-B8B3-DD75E4DB66C6Q33699243-85F9EE9C-D91B-4B2C-81C9-B5A53CF856C1Q33700531-CA560AB5-9BA7-4BC8-9945-DD94B8C6A728Q33729971-7ECBDA82-3FD4-425B-BAB0-9FF075A0B354Q33822080-21665E40-8926-4CB1-9AEC-FDD99F1113D3Q33858819-B69AB80A-B654-4CE1-9FAB-11233519187DQ33877654-A85E6901-643A-4956-82E0-E3E9EB617D41Q33927978-C923B485-79E1-4D20-B622-ABA4C2A0D93BQ33951481-D1BADF54-A808-4A78-B6B3-47292F41989AQ34235750-2755A32D-1923-4C65-9A5D-20B0AA22EADCQ34371078-34D9AFFA-9870-4B23-BA08-24FC13ADE985Q34390837-AF7A8872-E792-4A8C-8FB7-241D9DB40C9CQ34975323-985D1822-A9E9-40D3-83E3-88405283F35AQ35009437-D79A03BF-3749-41F8-959C-972F6C080295Q35009446-951C9628-3289-4D89-B313-2B1F20A57B90Q35061526-F99BDD29-D667-4353-A873-C328DB2769E6Q35082503-5817C994-5155-4D42-A0C7-AEFDB51B62D8Q35153794-8A70FB82-A290-4182-8ECF-2DF80BE422A5Q35172803-5CE0AD71-1587-4664-B746-1B09108BDCBDQ35419876-216C2594-9FFE-4DEB-BD75-298A3E17F8A6Q35447899-D0ABEBC8-0EC6-4AF5-8FCD-D530D10AE812Q35655956-1CB535E0-661A-4280-B16B-5BFC5748910BQ35669239-9D24114D-2269-4A79-A3A7-AEA701A37E92Q35687910-10CDDF10-1C1B-4DB8-B33A-9566A504440EQ36015211-887E5AE3-71D9-4A7E-9C82-5F1F540030E9Q36481117-41C71F9D-8926-4F82-A8E0-910CB25A423BQ36608413-11A25153-9B61-4E46-8C02-F4737EB86FEFQ36618819-8A4815D6-ADDE-4917-9EFD-289E9E7A3BA6Q36640231-A0544F01-2C53-4839-A082-EF8A2275D3D8Q36799606-E9DB1628-4A20-4688-B3FE-10B6C28DAF52Q36842008-3066701D-5827-403E-9143-4756FEAAE9A6Q36842035-473BC3B8-1527-4325-B2CC-4F6E4EA9CF23Q36895068-7C7DBE18-FE6F-4BD0-99BF-F81582E73AB3
P2860
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@ast
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@en
type
label
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@ast
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@en
prefLabel
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@ast
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@en
P2093
P2860
P1433
P1476
The oncoprotein LMO2 is expres ...... and in human B-cell lymphomas.
@en
P2093
Anne S Hammer
Behnaz Taidi
David Y Mason
Izidore S Lossos
Margaret Jones
Ronald Levy
Shuchun Zhao
Stephen Hamilton Dutoit
Yasodha Natkunam
P2860
P304
P356
10.1182/BLOOD-2006-08-039024
P407
P577
2006-10-12T00:00:00Z